Moody’s affirms ‘A1’ rating on Dana-Farber Cancer Institute

Moody’s Investors Service affirmed its “A1” rating on Boston-based Dana-Farber Cancer Institute.

Advertisement

The rating affirmation is a result of several factors, including the institute’s prominence in cancer research, strong fundraising capabilities, improved operating performance and long-standing relationships with other leading academic medical centers.

The outlook is stable.

More articles on healthcare finance:
State-by-state breakdown of 102 rural hospital closures
93% of MIPS clinicians got bonuses in 2017
Hospital revenue cycle trends to watch in 2019 — 8 thoughts

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.